Antimicrobial susceptibility analysis of isepamicin combination treatments in Mycobacterium abscessus species

IF 1.9 Q3 INFECTIOUS DISEASES Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Pub Date : 2024-07-15 DOI:10.1016/j.jctube.2024.100464

{"title":"Antimicrobial susceptibility analysis of isepamicin combination treatments in Mycobacterium abscessus species","authors":"","doi":"10.1016/j.jctube.2024.100464","DOIUrl":null,"url":null,"abstract":"<div>This study evaluated the antimicrobial potency of the combination of isepamicin (ISP) for Mycobacterium abscessus species (MABS). 34 clinical MABS strains were isolated from clinical samples. Of them, 11 (32.4 %) were M. abscessus subsp. abscessus (Mab), 22 (64.7 %) were M. abscessus subsp. massiliense (Mma), and one (2.9 %) was M. abscessus subsp. bolletii (Mbo). We compared susceptibility to sitafloxacin (STFX)-ISP and clarithromycin (CLR)-ISP combinations with those of the antimicrobial agents alone, and synergistic effects were observed in 41.2 % and 17.6 % when treated with STFX-ISP and CLR-ISP. By hierarchical cluster analysis, the isolates divided into treatment-sensitive and treatment-resistant groups. Non-Mma or rough colony isolates were significantly likely to belong to the treatment-sensitive group (p = 0.024, p < 0.001, respectively). These results suggest that the ISP-containing combination could be a new therapeutic strategy for MABS, especially in cases of non-Mma: treatment-refractory subspecies, and rough morphotypes: high-virulence morphotypes.</div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000512/pdfft?md5=b7ba95048e11d7c35e4529da77e36cba&pid=1-s2.0-S2405579424000512-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579424000512","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

This study evaluated the antimicrobial potency of the combination of isepamicin (ISP) for Mycobacterium abscessus species (MABS). 34 clinical MABS strains were isolated from clinical samples. Of them, 11 (32.4 %) were M. abscessus subsp. abscessus (Mab), 22 (64.7 %) were M. abscessus subsp. massiliense (Mma), and one (2.9 %) was M. abscessus subsp. bolletii (Mbo). We compared susceptibility to sitafloxacin (STFX)-ISP and clarithromycin (CLR)-ISP combinations with those of the antimicrobial agents alone, and synergistic effects were observed in 41.2 % and 17.6 % when treated with STFX-ISP and CLR-ISP. By hierarchical cluster analysis, the isolates divided into treatment-sensitive and treatment-resistant groups. Non-Mma or rough colony isolates were significantly likely to belong to the treatment-sensitive group (p = 0.024, p < 0.001, respectively). These results suggest that the ISP-containing combination could be a new therapeutic strategy for MABS, especially in cases of non-Mma: treatment-refractory subspecies, and rough morphotypes: high-virulence morphotypes.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

脓肿分枝杆菌对异帕米星联合疗法的抗菌药敏感性分析

本研究评估了异帕米星（ISP）复方制剂对脓肿分枝杆菌（MABS）的抗菌效力。从临床样本中分离出 34 株临床 MABS 菌株。其中，11 株（32.4%）为脓肿分枝杆菌（Mab），22 株（64.7%）为脓肿分枝杆菌亚种（Mma），1 株（2.9%）为脓肿分枝杆菌亚种（Mbo）。我们比较了西他沙星（STFX）-ISP 和克拉霉素（CLR）-ISP 组合与单独使用两种抗菌剂的敏感性，结果发现，在使用 STFX-ISP 和 CLR-ISP 治疗时，分别有 41.2% 和 17.6% 的患者对这两种抗菌剂产生了协同作用。通过分层聚类分析，分离菌株分为对治疗敏感和对治疗耐受两组。非 Mma 或粗糙菌落的分离物很可能属于治疗敏感组（分别为 p = 0.024、p < 0.001）。这些结果表明，含 ISP 的复方制剂可能是治疗 MABS 的一种新策略，尤其是在非 Mma：难治亚种和粗糙形态：高致病力形态的情况下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.00

自引率

5.00%

发文量

审稿时长

30 weeks

期刊介绍： Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.